Dr. Weinstein treats patients with all forms of childhood and adolescent cancer. Her primary areas of expertise include retinoblastoma (the most common form of eye cancer in children), pediatric lymphomas (both Non-Hodgkin and Hodgkin subtypes and post-transplantation lymphomas), and a group of disorders called the histiocytoses, including Langerhans Cell Histiocytosis (LCH) and Hemophagocytic Lymphohistiocytosis (HLH). She aims to provide high-quality, personalized care to her patients and provide opportunities for her patients to enroll on clinical trials.

Dr. Weinstein's clinical and research areas of interest include retinoblastoma, pediatric lymphoma (both Non-Hodgkin and Hodgkin subtypes and post-transplantation lymphomas), and the histiocytoses. Our retinoblastoma team includes oncologists, ophthalmologists, interventional radiologists, social workers, genetics counselor, clinical research specialists, as well as researchers in the laboratory. The Retinoblastoma Center of Excellence is currently working on novel approaches to treating retinoblastoma. Lurie Children's is one of the few centers in the country to offer intra-arterial chemotherapy for the treatment of intraocular retinoblastoma. Additionally, Dr. Weinstein is one of the few oncologists in the Chicagoland area specializing in histiocytic disorders, such as Langerhans Cell Histiocytosis (LCH) and Hemophagocytic lymphohistiocytosis (HLH). Additionally, Dr. Weinstein heads the multidisplinary Cancer Predisposition Program at Lurie Children's Hospital. Working with genetic counselors and clinicians in many divisions, this program provides comprehensive genetic counseling services, directs personalized genetic testing for patients and families, and provides comprehensive, multidisplinary care to patients with hereditary cancer syndromes.